News

Filter

Current filters:

PfizerNaproxen

1 to 9 of 58 results

NicOx "on the brink" of becoming a drugmaker

09-03-2009

French drug developer NicOx SA says it hopes to transform itself into a standalone sales-generating…

AnaproxAnaprox DSInomaxMerck KGaANaprosynNaproxenNitric OxidePfizer

NicOx shares up 44% on strong late-stage data

10-11-2008

Shares in NicOx SA rose as much as 44% on November 4 after the French drug developer reported strong…

AnaproxAnaprox DSCelebrexcelecoxibInomaxMerck KGaANaprosynNaproxenNitric OxidePfizerRofecoxibVioxx

NicOx swings to a loss in 1st-qtr p R&D costs

26-05-2008

French drugmaker NicOx SA swung to a loss of 13.0 million euros ($20.2 million) in the first quarter…

AnaproxAnaprox DSDrug DiscoveryibuprofenMerck KGaAMotrinNaprosynNaproxenPfizer

Confusion reigns in the post-Vioxx musculoskeletal pain market

10-07-2006

A new global survey of primary care physicians (PCP) and people with chronic musculoskeletal pain reveals…

AnaproxAnaprox DSAspirinBayerBextraCelebrexcelecoxibCytotecibuprofenMerck KGaAMisoprostolMotrinNaprosynNaproxenPfizerRofecoxibValdecoxibVioxx

Celebrex causes less ulcers than naproxen, says study

03-07-2006

New data, presented at the annual European League Against Rheumatism meeting in Amsterdam, the Netherlands,…

AnaproxAnaprox DSAspirinBayerCelebrexcelecoxibNaprosynNaproxenPfizer

Study links Pfizer's painkiller Celebrex to an increased risk of myocardial infarction

13-03-2006

A new meta-analysis by Brent Caldwell et al, published in the Journal of the Royal Society of Medicine…

AnaproxAnaprox DSCelebrexcelecoxibibuprofenMotrinNaprosynNaproxenPfizer

New drugs from GSK, Novartis et al will restore arthritic pain market

12-12-2005

New drugs from GlaxoSmithKline, Novartis, NicOx and Pain Therapeutics will restore the drug market for…

AnaproxAnaprox DSBextraGlaxoSmithKlineGSKInomaxMerck KGaAnaltrexoneNaprosynNaproxenNitric OxideNovartisPfizerReviaRofecoxibValdecoxibVioxx

1 to 9 of 58 results

COMPANY SPOTLIGHT

Menarini

Back to top